Diagnostic value of 11C-metomidate Positron Emission Tomography/Computerized Tomography (PET/CT) for the evaluation of primary aldosteronism: a pilot study

Completed

• Conditions: primary aldosteronism - Conn's syndrome - overactive adrenal gland with excessive secretion of aldosterone; 10001353

• Registration Number: NL-OMON35185
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

- adult subjects (at least 18 years of age)
- primary aldosteronism with complete diagnostic work-up including succesfully performed adrenal venous sampling

Exclusion Criteria

- diabetes melltus (type 1 or type 2)
- use of ketoconazole, metyrapone or cytostatic drugs in previous 6 months
- pregnancy
- severe contrast allergy
- serious comorbidities precluding surgery
Note: last 3 conditions are exclusion criteria for adrenal venous sampling, not for 11C-metomidate PET/CT

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To establish with PET whether 11C-metomidate is selectively taken up by adrenal<br /><br>gland tissue with autonomic hypersecretion of aldosterone and that the<br /><br>distribution of tracer uptake by the adrenal glands (unilateral versus<br /><br>bilateral) is concordant with the results of AVS. Results are presented as<br /><br>percentages with 95%-confidence intervals. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>